Digestive Disease Week (DDW) 2024

In patients with HRS accompanied by rapidly progressive worsening in kidney function, an interruption of terlipressin dose does not appear to hinder the achievement of HRS reversal, according to a post hoc analysis of data from the CONFIRM study presented at DDW 2024

Among adults with moderate-to-severe active ulcerative colitis (UC), treatment with guselkumab, a dual-acting interleukin-23 inhibitor, led to clinical remission at week 44, according to initial data from the phase III QUASAR maintenance study presented at DDW 2024.

Treatment with linaclotide significantly improved abdominal symptoms and the frequency of complete spontaneous bowel movements (CSBMs) among adult and elderly patients with irritable bowel syndrome with constipation (IBS-C), according to the pooled analysis of three phase III trials presented at DDW 2024.

Ablating the gastric fundus to reduce the production of the hunger hormone ghrelin helps women curb their appetite and lose body weight in the ABLATE-WEIGHT first-in-human trial.

A 1-day regimen of octreotide infusion, along with endoscopic therapy for variceal bleeding, does not appear to be inferior to the standard 5-day regimen in the prevention of rebleeding and all-cause mortality at 6 weeks, according to the preliminary results of a study.